X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Tom Wilbur

Tom Wilbur is Director of Public Affairs at PhRMA focusing on message development and opinion research. Prior to joining PhRMA in 2019, Tom worked on Capitol Hill and on political campaigns for nearly a decade, most recently responsible for communications, campaigns and strategy for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom is a proud Michigander and outside of the virtual office enjoys reading, running, hiking, golfing, and spending time with friends and family.

Recent Posts

End of year Part D reading List

By Tom Wilbur  |    December 18, 2020
Happy Holidays, Part D readers, and thank you for following along this year as we explored the impact of Medicare Part D and the important role the program plays for seniors and those with...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    December 18, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

Insights from the election: Meeting voters where they are on health care

By Tom Wilbur  |    December 15, 2020
The 2020 election was defined by a wide range of unique, and in some cases, unprecedented factors. From a global pandemic to never before seen rates of mail-in ballot casting and record voter...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    December 7, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

Final rebate rule represents right way to change Medicare

By Tom Wilbur  |    December 1, 2020
As Washington policymakers look to make changes to Medicare and our health care system overall, there are right ways and wrong ways to address the challenges that seniors and patients face....   Read More

Deep dive: The issues that drove the 2020 vote

By Tom Wilbur  |    November 13, 2020
The 2020 election provided much-needed clarity on the issues that matter most to Americans. Here are three key takeaways:   Read More

New video: See how strong IP protections lead to stronger treatments for patients

By Tom Wilbur  |    November 9, 2020
Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. A strong IP...   Read More

Voters want to address the real drivers of health care costs for patients and the system

By Tom Wilbur  |    November 2, 2020
COVID-19 has understandably reshaped the health care conversation surrounding the upcoming election, with roughly one-fifth of voters citing the coronavirus pandemic as the priority issue heading...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    October 28, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

How does Medicare Part D impact you?

By Tom Wilbur  |    October 21, 2020
Whether you are a direct beneficiary, a caregiver or simply an American taxpayer, Medicare Part D impacts you. The Medicare Part D program, which was created by the Medicare Modernization Act...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates